HIV-189.6 Gag expressed from a replication competent HSV-1 vector elicits persistent cellular immune responses in mice

Academic Article

Abstract

  • We have constructed a replication competent, γ134.5-deleted herpes simplex virus type-1 (HSV-1) vector (J200) that expresses the gag gene from human immunodeficiency virus type-1, primary isolate 89.6 (HIV-189.6), as a candidate vaccine for HIV-1. J200 replicates in vitro, resulting in abundant Gag protein production and accumulation in the extracellular media. Immunization of Balb/c mice with a single intraperitoneal injection of J200 elicited strong Gag-specific CD8 responses, as measured by intracellular IFN-γ staining and flow cytometry analysis. Responses were highest between 6 weeks and 4 months, but persisted at 9 months post-immunization, the last time-point evaluated. These data highlight the potential utility of neuroattenuated, replication competent HSV-1 vectors for delivery of HIV-1 immunogens. © 2007 Elsevier Ltd. All rights reserved.
  • Published In

  • Vaccine  Journal
  • Digital Object Identifier (doi)

    Author List

  • Parker SD; Rottinghaus ST; Zajac AJ; Yue L; Hunter E; Whitley RJ; Parker JN
  • Start Page

  • 6764
  • End Page

  • 6773
  • Volume

  • 25
  • Issue

  • 37-38